Loading…
Dual Responsive Magnetic DCR3 Nanoparticles: A New Strategy for Efficiently Targeting Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is a major cause of cancer deaths globally. Unlike traditional molecularly targeted drugs, magnetically controlled drug delivery to micro/nanorobots enhances precision in targeting tumors, improving drug efficiency and minimizing side effects. This study develops a dua...
Saved in:
Published in: | Small (Weinheim an der Bergstrasse, Germany) Germany), 2024-11, p.e2402909 |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Article |
Language: | English |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Hepatocellular carcinoma (HCC) is a major cause of cancer deaths globally. Unlike traditional molecularly targeted drugs, magnetically controlled drug delivery to micro/nanorobots enhances precision in targeting tumors, improving drug efficiency and minimizing side effects. This study develops a dual-responsive, magnetically controlled drug delivery system using PEGylated paramagnetic nanoparticles conjugated with decoy receptor 3 (DCR3) antibodies. The clusters demonstrate capabilities for long-range, magnetically driven control and molecular chemotaxis. Paramagnetic PEGylated particles form vortex- and liquid-like drug moieties within a magnetically controlled system. Vortex-like nanoparticle clusters exhibit high controllability and countercurrent movement, while liquid-nanoparticle robot clusters display greater deformability. Upon loading with DCR3 antibodies, the particles navigate along DCR3-protein gradients in blood and tissue, effectively targeting liver tumor sites in vivo. Clusters of DCR3-coupled magnetic nanoparticles target cells that highly express DCR3, thereby effectively inhibiting tumor cell proliferation and migration. Compared with conventional nanomedicine, DCR3-coupled magnetic nanoparticle clusters are capable of delivering controlled drugs over long distances and responding in a molecular-targeting manner. This research is expected to significantly impact the field of precise tumor drug delivery. |
---|---|
ISSN: | 1613-6829 1613-6829 |
DOI: | 10.1002/smll.202402909 |